Day: June 26, 2025

Kymera + Sanofi Collab Update: IRAK4 Degrader KT-485 Moves Forward

Sanofi will advance KT-485/SAR447971, an oral, highly potent and selective IRAK4 degrader for immuno-inflammatory diseases, into clinical trials.